Onkure Therapeutics Inc
OKUR2.179USD
-0.021-0.95%
交易中 （美東）報價延遲15分鐘
USD0.000盤前交易 (美東)
29.29M總市值
虧損本益比TTM
單季報
單季報+年報
單季報
年報
YOY
隱藏空白列
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
營業費用
72.92%17.00M
35.15%33.80M
-77.67%4.66M
-69.75%6.36M
-39.02%9.83M
71.72%25.01M
50.92%20.89M
69.25%21.04M
23.88%16.12M
37.07%14.56M
8.53%13.84M
34.71%12.43M
80.41%13.02M
69.96%10.62M
150.09%12.75M
149.47%9.23M
60.24%7.21M
--6.25M
--5.10M
--3.70M
--4.50M
研發費用
51.90%13.01M
112.22%37.36M
-93.36%904.00K
-95.90%590.00K
-22.06%8.57M
69.97%17.60M
37.07%13.62M
77.08%14.40M
18.46%10.99M
45.87%10.36M
6.65%9.94M
29.51%8.13M
69.55%9.28M
38.73%7.10M
110.29%9.32M
122.90%6.28M
52.93%5.47M
--5.12M
--4.43M
--2.82M
--3.58M
折舊攤銷及損耗
1225.00%212.00K
1313.64%622.00K
-72.09%12.00K
-71.43%12.00K
-60.98%16.00K
76.00%44.00K
95.45%43.00K
90.91%42.00K
115.79%41.00K
47.06%25.00K
69.23%22.00K
120.00%22.00K
90.00%19.00K
70.00%17.00K
44.44%13.00K
11.11%10.00K
11.11%10.00K
--10.00K
--9.00K
--9.00K
--9.00K
營業利潤
-72.92%-17.00M
-35.15%-33.80M
77.67%-4.66M
69.75%-6.36M
39.02%-9.83M
-71.72%-25.01M
-50.92%-20.89M
-69.25%-21.04M
-23.88%-16.12M
-37.07%-14.56M
-8.53%-13.84M
-34.71%-12.43M
-80.41%-13.02M
-69.96%-10.62M
-150.09%-12.75M
-149.47%-9.23M
-60.24%-7.21M
---6.25M
---5.10M
---3.70M
---4.50M
淨非營業利息收入（費用）
利息收入
264.41%1.07M
--2.01M
----
----
--295.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
利息費用
----
--300.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
其他非經營性收入（費用）
----
-314.33%-3.11M
-42.55%972.00K
-33.49%1.00M
12.01%1.14M
50.94%1.45M
103.12%1.69M
1167.23%1.51M
4938.10%1.02M
5558.82%962.00K
4800.00%833.00K
891.67%119.00K
-1150.00%-21.00K
950.00%17.00K
240.00%17.00K
0.00%12.00K
-97.18%2.00K
---2.00K
--5.00K
--12.00K
--71.00K
稅前利潤
-67.00%-15.93M
-49.42%-35.19M
80.77%-3.69M
72.55%-5.36M
36.88%-9.54M
-73.19%-23.55M
-47.58%-19.20M
-58.63%-19.53M
-15.89%-15.11M
-28.22%-13.60M
-2.14%-13.01M
-33.59%-12.31M
-80.75%-13.04M
-69.63%-10.61M
-150.00%-12.73M
-149.96%-9.22M
-62.76%-7.21M
---6.25M
---5.09M
---3.69M
---4.43M
除稅後利潤
-67.00%-15.93M
-49.42%-35.19M
80.77%-3.69M
72.55%-5.36M
36.88%-9.54M
-73.19%-23.55M
-47.58%-19.20M
-58.63%-19.53M
-15.89%-15.11M
-28.22%-13.60M
-2.14%-13.01M
-33.59%-12.31M
-80.75%-13.04M
-69.63%-10.61M
-150.00%-12.73M
-149.96%-9.22M
-62.76%-7.21M
---6.25M
---5.09M
---3.69M
---4.43M
持續經營利潤
-67.00%-15.93M
-49.42%-35.19M
80.77%-3.69M
72.55%-5.36M
36.88%-9.54M
-73.19%-23.55M
-47.58%-19.20M
-58.63%-19.53M
-15.89%-15.11M
-28.22%-13.60M
-2.14%-13.01M
-33.59%-12.31M
-80.75%-13.04M
-69.63%-10.61M
-150.00%-12.73M
-149.96%-9.22M
-62.76%-7.21M
---6.25M
---5.09M
---3.69M
---4.43M
歸属于母公司的淨利潤
-67.00%-15.93M
-49.42%-35.19M
80.77%-3.69M
72.55%-5.36M
36.88%-9.54M
-73.19%-23.55M
-47.58%-19.20M
-58.63%-19.53M
-15.89%-15.11M
-28.22%-13.60M
-2.14%-13.01M
-33.59%-12.31M
-80.75%-13.04M
-69.63%-10.61M
-150.00%-12.73M
-149.96%-9.22M
-62.76%-7.21M
---6.25M
---5.09M
---3.69M
---4.43M
歸屬普通股東的淨利潤
-67.00%-15.93M
-49.42%-35.19M
80.77%-3.69M
72.55%-5.36M
36.88%-9.54M
-73.19%-23.55M
-47.58%-19.20M
-58.63%-19.53M
-15.89%-15.11M
-28.22%-13.60M
-2.14%-13.01M
-33.59%-12.31M
-80.75%-13.04M
-69.63%-10.61M
-150.00%-12.73M
-149.96%-9.22M
-62.76%-7.21M
---6.25M
---5.09M
---3.69M
---4.43M
基本每股收益
96.09%-1.19
-33.38%-9.36
-94.52%-11.04
75.18%-1.60
-403.28%-30.37
-26.82%-7.02
-6.93%-5.68
-28.44%-6.46
-13.21%-6.03
-27.65%-5.54
-1.72%-5.31
-16.67%-5.03
-78.93%-5.33
-67.92%-4.34
-148.09%-5.22
-183.26%-4.31
-62.76%-2.98
---2.58
---2.10
---1.52
---1.83
稀釋每股收益
96.09%-1.19
-33.38%-9.36
-94.52%-11.04
75.18%-1.60
-403.28%-30.37
-26.82%-7.02
-6.93%-5.68
-28.44%-6.46
-13.21%-6.03
-27.65%-5.54
-1.72%-5.31
-16.67%-5.03
-78.93%-5.33
-67.92%-4.34
-148.09%-5.22
-183.26%-4.31
-62.76%-2.98
---2.58
---2.10
---1.52
---1.83
每股派息
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
貨幣單位
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
審計意見
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
